NCT00044148已完成2 期
The Effect of LY333531 on Albuminuria in Patients With Type 2 Diabetes A Pilot Clinical Trial
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 试验地点
- 15
研究概览
简要总结
The purpose of this study are to determine 1) Whether Ly333531 can reduce urinary albumin/creatinine excretion in patients with Type II diabetes and persistent albuminuria 2) Whether LY333531 reduces urinary TGF-B, 3) the safety of LY333531 and any side effects that may be associated with it.
研究设计
- 研究类型
- Interventional
- 主要目的
- Treatment
入排标准
- 年龄范围
- 30 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Type 2 diabetes mellitus
- •Greater than or equal to 30 years of age
- •Albumin to Creatinine ratio (greater than 200 mg/g and less than 2000 mg/g) 4)Without language barrier.
排除标准
- •Serum Creatinine greater than 2.0 mg/dl males or greater than 1.7 mg/dl females
- •B/P greater than 150 systolic and greater than 90 diastolic
- •Hemoglobin Alc greater than 11%
- •Liver Function Tests 2 times upper limit of normal
- •Poor medical or psychiatric risk.
研究者
研究点 (15)
Loading locations...
相似试验
招募中
2 期
The Evaluation of the Drug R3R01 for the Excretion of Protein in the Urine in Patients With Diabetic Kidney Disease.Diabetic Kidney DiseaseNCT06600412River 3 Renal Corp.60
尚未招募
4 期
Comparing Medications for Reducing Kidney Damage in Diabetes: A Study on Dapagliflozin Alone and with EplerenoneCTRI/2024/01/061952Dr Nikhil Kumar
已完成
4 期
Efficacy of Albumin for Acute Encephalopathy in Patients With CirrhosisHepatic EncephalopathyNCT00886925Hospital Universitari Vall d'Hebron Research Institute56
尚未招募
不适用
IMPROVEType 2 diabetesHigh AlbuminuriaNL-OMON23733niversity Medical Center Groningen36
已完成
2 期
A Study to Evaluate ASP8232 as Add-On Therapy to Angiotensin Converting Enzyme Inhibitor (ACEi) or Angiotensin Receptor Blocker (ARB) in Reducing Albuminuria in Patients With Type 2 Diabetes and Chronic Kidney DiseaseType 2 DiabetesChronic Kidney DiseaseNCT02358096Astellas Pharma Europe B.V.125